Viventia Bio registers $86.25 million stock for initial public sale

Leerink Partners, Cowen and Guggenheim Securities to assist with deal

By Devika Patel

Knoxville, Tenn., Oct. 21 – Viventia Bio Inc. will price its initial public offering of common stock with a 30-day greenshoe, according to a Form F-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $86.25 million of stock.

Leerink Partners, Cowen and Co. and Guggenheim Securities are the bookrunners.

Proceeds will be used for clinical trials, working capital, research and development and general corporate purposes.

The biologics oncology company is based in Winnipeg, Man. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “VITA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.